RecruitingPhase 3Drug trialLEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2The purpose of this study is to assess the efficacy and safety of the study drug, levosimendan (given orally), compared to placebo in participants with pulmonary hypertension with heart failure with preserved left ventricular ejection fraction (PH-HFpEF) as measured by the change in 6-Minute Walk Distance.